These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19246585)

  • 21. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
    Bosi E
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR
    Diabetologia; 2012 Jun; 55(6):1577-96. PubMed ID: 22526604
    [No Abstract]   [Full Text] [Related]  

  • 23. Chorea in hyperglycemia.
    Piccolo I; Sterzi R; Thiella G
    Diabetes Care; 1998 Oct; 21(10):1777. PubMed ID: 9773750
    [No Abstract]   [Full Text] [Related]  

  • 24. Metformin therapy in patients with type 2 diabetes complicated by heart failure.
    Inzucchi SE; Masoudi FA; McGuire DK
    Am Heart J; 2007 Dec; 154(6):e45. PubMed ID: 18035066
    [No Abstract]   [Full Text] [Related]  

  • 25. Glycemic treatment in type 1 and type 2 diabetes.
    Bloomgarden ZT
    Diabetes Care; 2006 Nov; 29(11):2549-55. PubMed ID: 17065700
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetes in the new General Medical Services contract: targets and adherence to metformin therapy.
    Kirby M
    Int J Clin Pract; 2005 Mar; 59(3):263-6. PubMed ID: 15857318
    [No Abstract]   [Full Text] [Related]  

  • 27. Choosing first-line therapy for management of type 2 diabetes.
    Graber MA; Darby-Stewart A; Dachs R
    Am Fam Physician; 2008 Jan; 77(1):16-7. PubMed ID: 18236820
    [No Abstract]   [Full Text] [Related]  

  • 28. Type 2 diabetes mellitus in youth: the complete picture to date.
    Gungor N; Hannon T; Libman I; Bacha F; Arslanian S
    Pediatr Clin North Am; 2005 Dec; 52(6):1579-609. PubMed ID: 16301084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations?
    Czupryniak L
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S22-5. PubMed ID: 20115928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes.
    Nolan JJ
    Diabetologia; 2010 Jul; 53(7):1247-9. PubMed ID: 20419286
    [No Abstract]   [Full Text] [Related]  

  • 31. FPIN's clinical inquiries. Metformin therapy and diabetes prevention in adolescents who are obese.
    Rodríguez JE; Shearer B; Slawson DC
    Am Fam Physician; 2007 Nov; 76(9):1357-8. PubMed ID: 18019881
    [No Abstract]   [Full Text] [Related]  

  • 32. Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?
    Rimareix F; Bauduceau B
    Ann Endocrinol (Paris); 2013 Jul; 74(3):207-10. PubMed ID: 23747137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study of hyperglycemia and cancer risk: response to Stattin et al.
    Bowker SL; Johnson JA
    Diabetes Care; 2007 Jul; 30(7):e77; author reply e78. PubMed ID: 17596500
    [No Abstract]   [Full Text] [Related]  

  • 34. American Diabetes Association. Resource guide 2005. Class action: type 2 pills update.
    McCarren M
    Diabetes Forecast; 2005 Jan; 58(1):RG6-9. PubMed ID: 15714615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should the algorithm for the treatment of type 2 diabetes be evidence-based?
    Guillausseau PJ
    Diabetologia; 2010 Sep; 53(9):2076-7. PubMed ID: 20607513
    [No Abstract]   [Full Text] [Related]  

  • 36. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.
    Schernthaner G; Barnett AH; Betteridge DJ; Carmena R; Ceriello A; Charbonnel B; Hanefeld M; Lehmann R; Malecki MT; Nesto R; Pirags V; Scheen A; Seufert J; Sjohölm A; Tsatsoulis A; DeFronzo R
    Diabetologia; 2010 Jul; 53(7):1258-69. PubMed ID: 20352408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [2015 updated position statement of the management of hyperglycaemia in type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2015 Aug; 11(483):1518, 1520-5. PubMed ID: 26502577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Getting an extension.
    Diabetes Obes Metab; 2002 Mar; 4(2):139-40. PubMed ID: 11993444
    [No Abstract]   [Full Text] [Related]  

  • 39. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al.
    Lund SS; Vaag AA
    Diabetes Care; 2009 Jul; 32(7):e90-1; author reply e92-3. PubMed ID: 19564469
    [No Abstract]   [Full Text] [Related]  

  • 40. [A reply to Ake Sjoholm et al about new agents against type 2 diabetes: safety data prior to wide utilization or the other way round?].
    Karlsson EA; Palmér M; Malmström R
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1692. PubMed ID: 18590014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.